Centre de Recherche en Myologie, Inserm, Institut de Myologie, Sorbonne Université, F-75013 Paris, France.
Dementia Research Institute, Cardiff University, Cardiff CF10 3AT, UK.
Int J Mol Sci. 2021 Mar 5;22(5):2616. doi: 10.3390/ijms22052616.
Myotonic dystrophy type 1 (DM1) is the most complex and variable trinucleotide repeat disorder caused by an unstable CTG repeat expansion, reaching up to 4000 CTG in the most severe cases. The genetic and clinical variability of DM1 depend on the sex and age of the transmitting parent, but also on the CTG repeat number, presence of repeat interruptions and/or on the degree of somatic instability. Currently, it is difficult to simultaneously and accurately determine these contributing factors in DM1 patients due to the limitations of gold standard methods used in molecular diagnostics and research laboratories. Our study showed the efficiency of the latest PacBio long-read sequencing technology to sequence large CTG trinucleotides, detect multiple and single repeat interruptions and estimate the levels of somatic mosaicism in DM1 patients carrying complex CTG repeat expansions inaccessible to most methods. Using this innovative approach, we revealed the existence of de novo CCG interruptions associated with CTG stabilization/contraction across generations in a new DM1 family. We also demonstrated that our method is suitable to sequence the DM1 locus and measure somatic mosaicism in DM1 families carrying more than 1000 pure CTG repeats. Better characterization of expanded alleles in DM1 patients can significantly improve prognosis and genetic counseling, not only in DM1 but also for other tandem DNA repeat disorders.
肌强直性营养不良 1 型(DM1)是由不稳定的 CTG 重复扩展引起的最复杂和可变的三核苷酸重复疾病,在最严重的情况下,可达 4000 个 CTG。DM1 的遗传和临床变异性取决于传递父母的性别和年龄,但也取决于 CTG 重复数、重复中断的存在和/或体细胞不稳定性的程度。目前,由于分子诊断和研究实验室中使用的金标准方法的限制,难以同时准确确定 DM1 患者的这些致病因素。我们的研究表明,最新的 PacBio 长读测序技术在测序大型 CTG 三核苷酸、检测多个和单个重复中断以及估计携带复杂 CTG 重复扩展的 DM1 患者体细胞镶嵌水平方面具有效率,这些扩展无法通过大多数方法获得。使用这种创新方法,我们揭示了在一个新的 DM1 家族中存在与 CTG 稳定/收缩相关的从头 CCG 中断,这种现象跨越了几代人。我们还证明了我们的方法适用于测序 DM1 基因座,并测量携带超过 1000 个纯 CTG 重复的 DM1 家族中的体细胞镶嵌。更好地描述 DM1 患者的扩增等位基因可以显著改善预后和遗传咨询,不仅在 DM1 中,而且在其他串联 DNA 重复疾病中也是如此。